Evidence map›Paper›PMID 26294737›Full record

ArticleHaematologica2015

Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology.

Simon Noble, Axel Matzdorff, Anthony Maraveyas, Majbrit V Holm, Giovanni Pisa

Open access · goldAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Quality of life in oncological patients with venous thromboembolic disease.Research and practice in thrombosis and haemostasis · 2024
    Review
  7. Review
  8. Review
  9. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Article
  10. Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Article
  11. Review
  12. Review
  13. Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022
    Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Simon NobleMarie Curie Palliative Care Research Centre, Cardiff University, Cardiff Wales, UK simon.noble@wales.nhs.uk.
Axel MatzdorffOncology Center at Caritasclinic Saarbrücken, Germany.
Anthony MaraveyasHull York Medical School, Queens Centre Oncology and Hematology, Hull, UK.
Majbrit V HolmLEO Pharma A/S, Ballerup, Denmark.
Giovanni PisaKantar Health GmbH, Munich, Germany.
Cardiff University · GBcts CaritasKlinikum Saarbrücken · DEHull York Medical School · GBKantar (Germany) · DELeo Pharma (Denmark) · DK

Funding

Marie Curie MCCC-FCO-11-C
6 · The paper itself

Abstract

Low molecular weight heparins have demonstrated superiority over coumarins in the extended treatment of cancer-associated thrombosis and are recommended as first-line therapy in clinical guidelines. Non-vitamin K oral antagonists are yet to be evaluated against low molecular weight heparin for this indication. Nevertheless, a perception that patients favor oral anticoagulants over injections may lead to an increased prescribing of warfarin or non-vitamin K oral antagonists despite the evidence gap. There has been no evaluation of cancer patient preferences for anticoagulants and whether such an evidence gap is an acceptable trade-off for patients prescribed orals. We conducted a study to assess what features are most important to CAT patients regarding their choice of anticoagulant. Two modules were applied: Initial in-depth interviews with 9 patients diagnosed with cancer-associated thrombosis, and thereafter quantitative research, where a further 100 patients completed a choice-based-conjoint exercise, where 15 different scenarios were presented to identify the most important attributes of an anticoagulant. Seventy percent of the patients were treated with injected medication (low molecular weight heparin) and 30% with oral medications. Patients most valued an anticoagulant with minimal interference with their cancer treatment (39%), low thrombosis recurrence rate (24%), and low risk of major bleed (19%). Preference for oral administration over injection had moderate importance (13%). The results show that patients prefer an anticoagulant that does not interfere with their cancer treatment, suggesting the primacy of the cancer disease over venous thromboembolism in these patients. Patients also favor efficacy and safety over convenience of route of administration.

Indexed as

Patient PreferenceAdministration, OralAgedAged, 80 and overAnticoagulantsFemaleHumansMaleMiddle AgedNeoplasmsThrombosisAnticoagulants

Identifiers

PMID26294737
PMCPMC4825304
OpenAlexW2174370443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.